G1 Therapeutics Inc., of Research Triangle Park, N.C., has filed for a $115 million IPO. The number of shares and share price have not yet been disclosed. The company anticipates using net proceeds to support clinical work on its CDK4/6 inhibitors, including intravenously administered trilaciclib, which is in a phase IIa trial in small-cell lung cancer and a phase II study in triple-negative breast cancer, with initial data expected in 2018. An oral compound, G1T-38, is expected to start a phase II study in combination with an EGFR inhibitor in non-small-cell lung cancer next year. J.P. Morgan, Cowen and Co., Needham & Co. and Wedbush Pacgrow are acting as underwriters. G1 seeks a listing on Nasdaq under the ticker GTHX.

Sorrento Therapeutics Inc., of San Diego, closed its public offering of about 23.6 million shares priced at $2 apiece for net proceeds of about $43.5 million. Proceeds will be used to resubmit an NDA for Ztlido, a next-generation lidocaine patch, as well as to support IND-enabling studies and phase I trials for its CD38 CAR T candidate and its c-MET antibody-drug conjugate. Funds will also support preclinical work, general research and development and corporate purposes. Cantor Fitzgerald & Co. acted as the lead book-running manager, FBR Capital Markets & Co. acted as a joint book-running manager, Oppenheimer & Co. and Aegis Capital Corp. acted as co-lead managers and Joseph Gunnar & Co., Rodman & Renshaw and Roth Capital Partners acted as co-managers.

Tocagen Inc., of San Diego, closed its IPO, including the underwriters' exercise of their option to purchase an additional 1.275 million shares at the $10 per share offering price. The total number of shares sold was 9.8 million, with gross proceeds of about $97.8 million. Proceeds from the IPO will help advance the firm's FDA breakthrough-designated candidates, Toca 511 and Toca FC, currently part of a phase II/III trial that could potentially support registration. Top-line data from the phase II portion of the study are expected in 2018. Leerink Partners LLC, Evercore Group LLC and Stifel, Nicolaus & Co. Inc. acted as joint book-running managers.